Early Ageing During Therapy in AYA Cancer Patients

Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · Sep 21, 2021

Keywords

ClinConnect Summary

This clinical trial, titled "Early Ageing During Therapy in AYA Cancer Patients," is studying how cancer treatments affect young adults aged 18 to 39. The researchers want to understand if these treatments lead to changes that make patients feel older, both physically and mentally. The trial focuses on various types of cancer, including leukemia, lymphoma, testicular cancer, and breast cancer, among others. Participants will have measurements taken before they start their treatment and again one year later.

To be eligible for the study, participants must be diagnosed with one of the specified cancers and scheduled to begin treatment aimed at curing their illness, which may include surgery, chemotherapy, or radiation. However, those who have had previous cancer treatments or are receiving certain advanced therapies are not eligible. If you or someone you know fits this description, participating in this trial could help researchers learn more about how cancer therapy impacts young adults' health and well-being over time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18-39 years at cancer diagnosis
• • Having a histologically and/or cytologically confirmed cancer diagnosis, including leukemia, (non-)Hodgkin lymphoma, testicular cancer, osteosarcoma, Ewing sarcoma, breast cancer, and cervical cancer.
• • Scheduled to start systemic therapy with curative intent. Allowed treatments (concurrent or sequential) are: surgery, radiotherapy, chemotherapy, antibodies.
• Exclusion Criteria:
• • patients who are not able to understand the patient information letter and informed consent form
• • patients who will be treated with immune checkpoint inhibitors or targeted therapy with inhibitors of angiogenesis
• • patients who have been treated with systemic therapy or radiotherapy for a previous malignancy (exceptions: in situ carcinoma of the cervix or uterus and adequately treated basal and squamous cell carcinoma of the skin).